Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Active, not recruiting · NCT05710666 · Registry updated 2024-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | HER2-positive Breast Cancer | Active, not recruiting | Phase 2 | 2024-08-05 | NCT05710666 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Trials Ireland | 26 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beaumont Hospital | Dublin | Ireland | 1 |
| Cork University Hospital | Cork | Ireland | 2 |
| Saint Vincent's University Hospital | Dublin | Ireland | 1 |
| University Hospital Galway | Galway | Ireland | 1 |
| University Hospital Limerick | Limerick | Ireland | 1 |